CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
CRISPR-mediated gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease resulted in functional human leukocytes in mice after transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [24]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197 · cited 1×
“CRISPR/Cas9, guided by a single-guide RNA, achieves efficient doublestranded DNA breaks (9, 10).”
BackgroundLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Genome editing in rice and wheat using the CRISPR/Cas system
Shan, Q., Wang, Y., Li, J., & Gao, C. (2014) · Nature Protocols · doi:10.1038/nprot.2014.157 · Cited by 763
Research works printed but not linked: 1
- J. A. Doudna E. J. Sontheimer Eds. The Use of CRISPR/Cas9 ZFNs and TALENs in Generating Site-Specific Genome Alterations vol. 546 of Methods in Enzymology (Academic Press 2014) pp. xix–xx.
Cited by
Items 201–264 of 264
Ravin, S. S. D., Brault, J., Meis, R. J., Li, L., Theobald, N., Bonifacino, A. C., Lei, H., Liu, T., Koontz, S. M., Corsino, C. I., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003224 · Cited by 4
“Moreover, we and others have demonstrated efficient in vitro delivery of mRNA to human CD34(1) HSCs with resultant high viability and function using EP in the context of gene editing.(13,14)”
MethodSelf-citationPrecise somatic genome editing for treatment of inborn errors of immunity
Meng, Q., Sun, H., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960348 · Cited by 4
“In later investigations for correcting a point mutation in exon 7, CRISPR/Cas9 was used in conjunction with an ssDNA oligonucleotide repair template to achieve moderate levels of gene correction (102).”
MethodTreating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing
Eguizábal, C., Herrera, L., Inglés‐Ferrándiz, M., & Belmonte, J. C. I. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01964-5 · Cited by 4
“For example, De Ravin and colleagues [78] could Eguizabal et al.”
Molecular requirements for human lymphopoiesis as defined by inborn errors of immunity
Mina, E. D., Guérin, A., & Tangye, S. G. (2021) · Stem Cells · doi:10.1002/stem.3327 · Cited by 4
Saberi, F., Yousefi-Najafabadi, Z., Shams, F., Dehghan, Z., Ahmadi, S., Pilehchi, T., Noori, E., Esmaeelzadeh, Z., Bazgiri, M., Mohammadi, R., et al. (2025) · Current Gene Therapy · doi:10.2174/0115665232345516241119070150 · Cited by 3
Fereydani, N. M., Galehdari, H., Hoveizi, E., Alghasi, A., Ajami, M., Andashti, B., & Malayeri, A. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01465-x · Cited by 4
Ojeda-Pérez, I., Bustos, A., Selvaraj, S., Fañanas-Baquero, S., Alberquilla, O., Serrano, L.-J., Bonafont, J., García-Torralba, A., Torres-Ruiz, R., Rodríguez, S., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101615 · Cited by 3
Genome engineering with Cas9 and AAV repair templates, successes and pitfalls
Birling, M., Hérault, Y., & Pavlovic, G. (2025) · Mammalian Genome · doi:10.1007/s00335-024-10099-4 · Cited by 3
“Initially, rAAV has been used effectively as donor vec - tors for HDR in immune cells in both in vitro and in vivo settings (De Ravin et al. 2017; Dever et al. 2016; DeWitt et al. 2016; Sather et al. 2015; Wang et al. 2015; Yang et al. 2016; Yin et al. 2016).”
Severe Combined Immunodeficiency
Galant-Swafford, J., & Geng, B. (2021) · Springer eBooks · doi:10.1007/978-3-030-57157-3_8 · Cited by 3
Fañanas-Baquero, S., Morin, M., Fernández, S., Ojeda-Pérez, I., Dessy-Rodríguez, M., Giurgiu, M., Bueren, J. A., Moreno-Pelayo, M. Á., Segovia, J. C., & Bustamante, O. Q. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1104666 · Cited by 5
Zeng, J., Liang, X., Duan, L., Tan, F., Chen, L., Qu, J., Li, J., Li, K., Luo, D., & Hu, Z. M. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023280 · Cited by 6
Editing the Genome Ex Vivo Stem Cell Therapy
Fan, Y., & Chan, J. K. Y. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0148-2 · Cited by 3
Advancements in gene therapy for Wiskott–Aldrich syndrome: from early trials to emerging approaches
de Mambro, L., & Stilhano, R. S. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04099-6 · Cited by 2
“Vaccination protocols require avoiding live vaccines, with the annual influenza vaccine being an exception facilitating correction through homology-directed repair (HDR) when a donor DNA template is provided [44].”
Dib, C., Queenan, J. A., Willner, H., Swartzrock, L., Charlesworth, C. T., Denis, M., Davis, J. R., Mepani, R. J., Ho, K., Castro, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.010 · Cited by 2
Advances and applications of crispr-cas9 technology in medicine and agriculture
Nandal, K., Rathee, J., Dahiya, P., & Kaur, M. (2025) · International Journal of Molecular Biology and Biochemistry · doi:10.33545/26646501.2025.v7.i1b.86 · Cited by 3
Recent Progress in Genome Editing for Gene Therapy Applications: The French Perspective
Amendola, M., Bedel, A., Buj‐Bello, A., Carrara, M., Concordet, J., Frati, G., Gilot, D., Giovannangeli, C., Gutiérrez-Guerrero, A., Laurent, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.191 · Cited by 2
“13,27 This is problematic when we want to gene modify primary human T and B cells and HSCs since it is clear now that a minimum of living modified cells need to be reinfused in the patient for therapeutic efficiency.”
Gene Editing in Human Haematopoietic Stem Cells for the Treatment of Primary Immunodeficiencies
Bahal, S., Karaxhuku, K., & Santilli, G. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00618-x · Cited by 2
High-Level Correction of the Sickle Mutation is Amplified in Vivo During Erythroid DifferentiationPreprint
Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S., Shao, S. J., Hennig, F., Romero, Z. G., Fernandez, B. C., Said, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985189 · Cited by 2
Duran, T., Karaselek, M. A., Dağdelen, B., Küççüktürk, S., Guler, S. N., Keleş, S., & Reisli, İ. (2026) · Immunologic Research · doi:10.1007/s12026-026-09758-2 · Cited by 1
Radecke, S. M., Schwarz, K., & Radecke, F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.015 · Cited by 1
“This ssODN was taken from work of De Ravin et al.(36) 288 involving the CRISPR/Cas9/single-guide RNA system, where the endogenous CYBB locus 289”
MethodHarnessing the potential of CRISPR-Cas9 to advance the study of human fungal pathogens
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1375851 · Cited by 1
Abad, J. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.04.049 · Cited by 1
AIDS tedavisi için gen düzenleme çalışmaları
Akpınaroğlu, C. (2020) · Gene Editing · doi:10.29228/genediting.40387 · Cited by 1
Tatullo, M., Limongelli, L., Marano, R. M., Valletta, A., Tempesta, A., & Rengo, S. (2022) · Biocell · doi:10.32604/biocell.2022.020570 · Cited by 1
Godbole, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809356-6.00006-x · Cited by 1
Bazazzadegan, N., Hasanzad, M., & Abedini, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-4974-4_9 · Cited by 1
Gene Editing of Bruton's Tyrosine Kinase for Treatment of X-Linked Agammaglobulinemia
Gray, D. (2020) · eScholarship (California Digital Library) · Cited by 1
Human Bone Marrow Adipose Tissue is a Hematopoietic Niche for Leptin-Driven MonopoiesisPreprint
Yang, Z., Samant, A., Desai, A., DeSouza, T., Cirka, H., Ceesay, M., Kostyra, D. M., Joyce, S., Khair, L., Solivan-Rivera, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.29.555167 · Cited by 1
Enhancing the Efficiency of CRISPR/Cas9 Precise Gene Editing for Cystic Fibrosis Gene Therapy
Seigel, K. E. (2018) · TSpace (University of Toronto)
Jacob, K. J., & Virani, A. (2017) · Health Science Inquiry · doi:10.29173/hsi226
Bradshaw, G. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.180906
Eguizábal, C., Herrera, L., Inglés‐Ferrándiz, M., & Belmonte, J. C. I. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02281-1
Mohammed, Z. S., & Al-Kraity, W. R. H. (2021) · Medico-Legal Update · doi:10.37506/mlu.v21i2.2878
Gene Therapy in Cellular Immunodeficiencies
Fox, T., Booth, C., & Morris, E. C. (2021) · Rare diseases of the immune system · doi:10.1007/978-3-030-70107-9_19
[Gene editing for the treatment of primary immunodeficiency disease].
Liu, S., Fang, S., & An, Y. (2021) · PubMed · doi:10.7499/j.issn.1008-8830.2103150
Genome Editing in Organoid to Improve Understanding of Human Disease
Zhou, B., & Liang, Y. (2022) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-93056-1_9
Gene therapy for primary immune deficiencies
Kohn, D. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00058-2
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseasesPreprint
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D. N., Grindel, B. I., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L. K., Goedland, M., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-90150/v1
Rao, J. V., Naik, R. R., Venkanna, S., & Kumar, N. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815050837122010008
CRISPR/Cas9 system in hematopoietic stem cells: Basic research and clinical applications
Albayrak, E. (2023) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.40.1.31
Definitive Treatments for Chronic Granulomatous Disease with a Focus on Gene Therapy
Santilli, G., & Thrasher, A. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-23752-2_33
Amberger, M. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.81592
Living donor organ transplantation—gene therapy
Crane, A., Müller, Y. D., Bromberg, J. S., & Meier, R. P. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23571-9.00048-7 · Cited by 1
Gene Editing Approaches for Haematological Disorders
Ferrari, S., & Canarutto, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00053-6 · Cited by 1
MMEJ-mediated IDLV knock-in via CRISPR/Cas9 in human hematopoietic stem/progenitor cells.
Sakkal, A. (2023) · theses.fr (ABES) · doi:10.70675/678681caza0bdz47cbz8307zddd952dfde91
Principles of Treatment of Primary Immunodeficiencies
Ovadia, A., Marcus, N., & Roifman, C. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00113-7
della Volpe, L., Vacca, R., & Micco, R. D. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.103722 · Cited by 2
Gene editing technologies: Transformative approaches to chronic disease treatment
Balasubramaniam, B., & van der Hoeven, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00010-0
Application of genetic scissoring in the management of genetically related diseases
Ogunlakin, A. D., Olusegun, O. V., Olusegun, S., Anejukwo, D. S., Asaleye, O., Balogun, H., Adedoyin, O. G., Ojo, O. A., Ogunlakin, O. A., & Sonibare, M. A. (2025) · Dietary Supplements and Nutraceuticals · doi:10.31989/dsn.v4i8.1730
“CRISPR-corrected stem cells have restored red blood cell production [50] and increased fetal hemoglobin (HbF) offers symptom relief [51].”
CRISPR/Cas9: the future of human gene editing
Zulkifli, N. D., Sani, S. B. M., Wong, C. H., Mahadzan, M., Suhimi, M. H. A., Zulkifli, N., & Das, K. T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33947-9.00009-8
Das, S. (2023) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/cmfw-8166
Salekdeh, P. R., Ma’mani, L., Tavakkoly‐Bazzaz, J., Mousavi, H., Modaressi, M. H., & Salekdeh, G. H. (2021) · Figshare · doi:10.6084/m9.figshare.14355118
Discovery of novel functional sequences through the analysis of tiling CRISPR screens
Fiaux, P. C. (2021) · eScholarship (California Digital Library)
Identification de nouvelles approches thérapeutiques pour les lymphomes T périphériques
Krug, A. (2023) · theses.fr (ABES) · doi:10.70675/a7d03ecfz08c1z4eb2z8979z0a3888d49669
Singh, A., Kumar, R., Chauhan, P., Mallikarjuna, M., Thaker, R., & Sambhav, K. (2026) · Cureus · doi:10.7759/cureus.108691 · Cited by 2
“With gene editing, it is possible to improve chimeric antigen receptor T-cells (CAR-T) and natural killer cells by deleting inhibitory receptors, modulating exhaustion-related mechanisms, and optimizing antigen recognition [18].”
InfluentialAdvances in Gene Therapy for Chronic Granulomatous Disease
Siow, K. M., Tsapogas, P., Pastukhov, O., & Reichenbach, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-21135-4_19
Minaiyan, G., Aussel, C., Ammann, S., & Cathomen, T. (2026) · Human Gene Therapy · doi:10.1177/10430342261465555
“61 Hence, relatively low levels of corrected HSPCs can give rise to a suf fi cient pool of functional effector cells to restore immune competence.”
Chen, H., Kadzioch, N. P., Gapp, M., Yang, H.-H., Ruhle, A., Villamizar, J. M., Fuchs, T., Schmacke, N. A., Hornung, V., Speck, R. F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.741689
Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency
Wolff, J. H., Skov, T. W., Dorset, S. R., Sjelborg, J., Ravendran, S., Revenfeld, A. L., Haslund, D., Møller, A. M. J., Holm, M., Thomsen, M. K., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aec7031
Midena, F. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
CRISPR/Cas9‐Mediated Correction of the SLC25A38 Mutation in a Patient With Sideroblastic Anemia
Yazdanparast, S., Galehdari, H., Khatami, S. R., Hoveizi, E., & Jaseb, K. (2026) · The Journal of Gene Medicine · doi:10.1002/jgm.70114
Oh, S.-Y., Park, Y. S., Choi, B. H., Kim, H. S., Jung, S.-C., & Jo, I. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109133
Metadata
- Authors
- De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., Sweeney, C., Kardava, L., Moir, S., Viley, A., Natarajan, P., Su, L., Kuhns, D., Zarember, K. A., Peshwa, M. V., & Malech, H. L.
- Affiliations
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- MaxCyte (United States) (US)
- Leidos Biomedical Research Inc. (United States) (US)
- National Institutes of Health (US)
- Corresponding author
- Li, Linhong
- Malech, Harry L.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-01-11
- Volume
- 9
- Issue
- 372
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2577713652
- Semantic Scholar
- 531bffc692cccebccbf571ed886fd2766c50f091
- Cited by
- 258
- References
- 32
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 23 · 2023: 19 · 2022: 23 · 2021: 36 · 2020: 39 · 2019: 35 · 2018: 26 · 2017: 25
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intramural Research Program of NIAID
- NIH (Z01-A1-00644, Z01-A1-00988)
- Maryland Stem Cell Research Fund (#2015-MSCRFP-1752)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9 genome editing, X-linked chronic granulomatous disease, hematopoietic stem cells, CYBB gene, gene correction, engraftment
- MeSH terms
- NADPH Oxidase 2, Animals, Cell Differentiation, DNA Repair, Female, Granulomatous Disease, Chronic, Hematopoietic Stem Cells, Humans, Mutation, Oligonucleotides, Genetic Therapy, Mutagenesis, Mice, SCID, Mice, Inbred NOD, Antigens, CD34, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.